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Background: Colorectal cancers carrying the B-Raf V600E-mutation are associated with a poor prognosis. The purpose
of this study was to identify B-RafV600E-mediated traits of cancer cells in a genetic in vitro model and to assess the
selective sensitization of B-RafV600E-mutant cancer cells towards therapeutic agents.
Methods: Somatic cell gene targeting was used to generate subclones of the colorectal cancer cell line RKO
containing either wild-type or V600E-mutant B-Raf kinase. Cell-biologic analyses were performed in order to link
cancer cell traits to the BRAF-mutant genotype. Subsequently, the corresponding tumor cell clones were characterized
pharmacogenetically to identify therapeutic agents exhibiting selective sensitivity in B-RafV600E-mutant cells.
Results: Genetic targeting of mutant BRAF resulted in restoration of sensitivity to serum starvation-induced apoptosis
and efficiently inhibited cell proliferation in the absence of growth factors. Among tested agents, the B-Raf inhibitor
dabrafenib was found to induce a strong V600E-dependent shift in cell viability. In contrast, no differential sensitizing
effect was observed for conventional chemotherapeutic agents (mitomycin C, oxaliplatin, paclitaxel, etoposide,
5-fluorouracil), nor for the targeted agents cetuximab, sorafenib, vemurafenib, RAF265, or for inhibition of PI3
kinase. Treatment with dabrafenib efficiently inhibited phosphorylation of the B-Raf downstream targets Mek 1/2
and Erk 1/2.
Conclusion: Mutant BRAF alleles mediate self-sufficiency of growth signals and serum starvation-induced resistance
to apoptosis. Targeting of the BRAF mutation leads to a loss of these hallmarks of cancer. Dabrafenib selectively
inhibits cell viability in B-RafV600E mutant cancer cells.
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Colorectal cancer (CRC) is one of the most frequent
causes of cancer related morbidity and mortality [1]. In
advanced stages of colorectal cancer, individualized tumor
therapy with molecularly targeted agents has been intro-
duced into clinical practice. The antibody cetuximab,
which is directed against the epidermal growth factor re-
ceptor (EGFR), provides survival advantage in the sub-
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In CRC, BRAF is mutated with a prevalence of 9.6%
[3] and the T1799A mutation accounts for more than
80% of these mutation events, resulting in a hyperacti-
vating substitution of valine600 by glutamic acid [4].
CRC patients with tumors harboring the B-Raf V600E
mutation have a poor prognosis [2]. The mutant kinase
constitutively activates the mitogen activated cascade of
the mitogen-activated protein kinase (MAPK) pathway,
resulting in deregulation of MAPK target genes. In
addition to the pleiotropic functions of the MAPK path-
way, the mammalian target of rapamycin (mTOR) path-
way is likewise affected due to crosstalk via extracellular
signal regulated kinase (Erk) [5]. Furthermore, the B-RafLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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phenotypes, including resistance to apoptosis, genetic in-
stability, senescence, and complex mechanisms provid-
ing independence from extracellular growth signals [6].
For this study, we established an in vitro BRAF model
system ideally suited for pharmacogenetic analyses by
recombination of either V600E or wild-type BRAF in
the colorectal cancer cell line RKO. RKO exhibits all key
traits of a distinct subpopulation of colorectal cancer
patients, namely V600E mutant B-Raf, microsatellite in-
stability (MSI), and the CpG island methylator pheno-
type (CIMP) [7-9]. In addition, since RKO is wild-type
for KRAS, APC, and TP53, and lacks chromosomal in-
stability (CIN), all relevant molecular features of other
CRC subtypes are missing in these cells [10-13]. We
used this model system to study cancer cells traits de-
pending on B-RafV600E and to identify agents selectively
targeting BRAF-mutant cells.
Results and discussion
BRAF targeting in RKO
It has been shown that B-RafV600E is sufficient to pro-
mote proliferation via Erk 1/2 signaling independently of
exogenous growth factors and confers mechanisms to
evade apoptosis [14-16]. However, these results are pri-
marily based on non-quantitative RNA interference
(RNAi) methods which are prone to artifacts in mamma-
lian cells due to nonspecific defense mechanisms [17]. In
contrast, somatic cell gene targeting enables quantitative
knockouts of single alleles (Figure 1A) and the gener-
ation of endogenous models featuring well-defined gen-
etic backgrounds [18]. Utilizing this method, we have
disrupted BRAF alleles in the colorectal cancer cell line
RKO and established syngeneic clones which harbor a
single BRAF allele of either wild-type or mutant geno-
type. Despite its near-diploid karyotype and MSI pheno-
type, the colorectal cancer cell line RKO carries a stable
triplication of the BRAF gene locus (dup (7) (q21q36))
with one wild-type and two mutant alleles present in
parental cells [13]. This genotype was verified by DNA
sequencing in RKO-E1, a subclone obtained from RKO
that was found to be comparable to the parental cell line
in terms of morphology and proliferation (Figure 1B and
data not shown).
In the first targeting round, an oncogenic allele of
BRAF exon 15 was recombined and deleted by somatic
cell gene targeting to generate the cell clone RBOW
(RKO-derived BRAFonc/wt/-). Subsequently, either wild-
type or V600E-mutant B-Raf was disrupted by targeting
a second allele in RBOW, yielding six BRAF-mutant and
one wild-type clone from approximately 104 screened
colonies. Out of these double positive clones, BRAF
knockout cell lines RBO-1 and RBO-2 (RKO-derived
BRAFonc/-/- 1 and 2) as well as RBW-1 (RKO-derivedBRAFwt/-/-) were established (Figure 1B). The apparent
counterselection against inactivation of B RafV600E might
indicate the presence of an oncogene addiction for
B-RafV600E as a cancer cell trait in RKO [19].
For structural confirmation of the deleted alleles, DNA
sequencing was performed and all genotypes were veri-
fied (Figure 1B). Furthermore, all cells expressed BRAF
protein at comparable levels (Figure 1C). While the ex-
pression of Mek 1/2 and Erk 1/2 was independent of
serum concentration and BRAF status, the phosphoryl-
ation of these effector kinases was constantly active in
the BRAF-mutant clones but low in BRAF-wild-type
cells (Figure 1C). This was found to be independent of
the serum concentration, indicating that the phosphoryl-
ation status of Mek and Erk is dependent on mutant
BRAF in RKO.
Cell-biological phenotypes related to mutant BRAF
Under standard long-term cell culture conditions no dif-
ferences in morphology or growth were observed be-
tween the cell clones (Figures 1B and 2A). Expectedly,
decreased serum concentrations led to lower proliferation
rates in these cells, but exponential growth was sustained
under all applied conditions. However, the withdrawal of
serum resulted in the inhibition of cell growth of the wild-
type cells RBW-1 (Figure 2B and C).
It has been shown previously that BRAF wild-type cells
require glucose supply for survival whereas BRAF-mu-
tant cell clones maintain proliferation in low-glucose en-
vironments [20]. Here we show that the V600E mutation
of B-Raf also provides independency of serum-derived
growth signals in RKO and that targeting of oncogeni-
cally mutant BRAF is sufficient to deprive this vital fea-
ture of malignancy from the cells, thereby corroborating
previous reports [6]. Sustained proliferative signaling is
considered one of the major traits of cancer cells and is
therefore used as a target mechanism of individualized
therapy approaches including anti EGFR therapy strat-
egies in colorectal cancer [21,22].
In another context, mutant B-Raf induced cellular sen-
escence rather than proliferation [23,24]. However, sen-
escence can be overcome by phosphoinositide 3-kinase
(PI3K)/AKT signaling [24] which is hyperactivated in RKO
due to a PIK3CA mutation. By staining of senescence-
associated β-galactosidase activity [25] we examined
whether the differential proliferation rates observed upon
serum deprivation were attributable to cellular senescence.
Cellular senescence was detected at very low levels in less
than 5% of cells (Figure 2D-E), indicating that senescence
alone cannot explain the strong reduction in cell growth
observed upon withdrawal of serum.
Flow cytometry revealed a significant increase of apop-
totic cells in wild-type compared to mutant clones upon
withdrawal of serum (Figure 2F and G). Apoptosis was
Figure 1 Generation and validation of BRAF knockout cell lines. A: Schematic representation of the knockout procedure resulting in recombination
of BRAF exon 15 and substitution by a resistance cassette. B: Genealogy of the corresponding tumor cell clones. From the parental colorectal cancer
cell line RKO a single clone was generated by limiting dilution. Subsequently, a first oncogenically mutant allele (onc) was deleted by infection with
AAV-BRAF-Hyg virus and the cell line RBOW (RKO-derived clone BRAF-/onc/wt) was established. In a secondary targeting using AAV-BRAF-Neo virus
either the second V600E allele or the wild-type allele (wt) was targeted to generate RBO (RKO-derived clone BRAF-/-/onc) and RBW (RKO-derived
clone BRAF-/-/wt) clones. Genotypes were validated by A/T peak ratio in sequencing histograms. Microscopy scales: 250 μm× 150 μm. C: Aliquots
of RKO-E1 and knockout cell clones were incubated under different serum conditions, subsequently lyzed, and used for Western blot analysis.
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siderable levels in serum-starved RBW-1, while all other
samples showed full-length protein only (Figure 2H).
Consistent with RKO modeling a distinct subpopulation
of patients characterized by the presence of certain mo-
lecular features and the absence of others [7], no impli-
cation of p53 in apoptosis was observed (Figure 2H).
Since serum starvation is often used to model apoptosis
mediated via the PUMA pathway [26], we also ana-
lyzed PUMA protein levels. PUMA was found to be
highly abundant specifically in serum starved RBW-1
(Figure 2H). Consistent with data previously shown by
others, starvation-induced apoptosis is mediated by PUMA
in a p53-independent fashion in our experiments [27].Programmed cell death is a key feature of proliferation
control in homeostasis and overcoming apoptosis is con-
sidered another hallmark of cancer cells [28]. Since virtu-
ally all malignant cancer cells show apoptosis resistance,
the induction of apoptotic pathways is considered a par-
ticularly promising approach for therapeutic strategies
[29]. Our results show that in RKO this particular cancer
cell trait is modulated by and dependent on B-RafV600E
and that targeting mutant BRAF is sufficient to restore
sensitivity to caspase-dependent apoptosis after serum
withdrawal via p53-independent PUMA induction [27].
Complementing and extending previous studies, we thus
provide evidence from an endogenous and quantitative
genetic model of BRAF-mutant colorectal cancer cells,
Figure 2 Characterization of proliferation behavior. A-C: Proliferation rates of cells as assessed by manual counting. D-E: Staining of
senescence-associated β-galactosidase activity and quantification of senescent cells revealed no relevant amounts of cellular senescence to be
present in RBW-1 or other clones. Microscopy scale: 150 μm× 100 μm. F: In 10% FBS all cell lines showed similar cell cycle patterns in flow
cytometry. Reduction of serum led to aberrant patterns for RBW-1 compared to BRAF-mutant clones. G: Quantification of sub G1 fraction revealed
high amounts of cell death in RBW-1 after incubation with 0.5% FBS. H: Apoptosis was analyzed by Western blotting for cleaved caspase 3, p53,
and PUMA.
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unspecific cellular response or incomplete knockdown in
RNAi setups and, likewise, avoiding inter-species bias
potentially experienced in mouse models of colorectal
cancer [30].
Pharmacogenetic characterization
Hyperactivated Raf/Mek/Erk signaling has been sug-
gested to mediate resistance towards drug-induced cell
death [31,32]. However, data from prostate cancer cells
transfected with mutant BRAF showed that there might
be tumor entity-dependent differences [33]. Our model
system of corresponding tumor cells is ideally suited
to determine the B-RafV600E-specific effects of a com-
prehensive panel of widely used chemotherapeuticagents including crosslinking agents (oxaliplatin, mi-
tomycin C), a taxane (paclitaxel), a topoisomerase II
inhibitor (etoposide), and the nucleic acid metabolism in-
hibitor 5-fluorouracil. We found that the BRAF mutational
status did not have a detectable impact on chemosensitivity
towards any of these agents (Figure 3A-E). These findings
suggest that B-RafV600E does not significantly contribute
to resistance towards conventional chemotherapeutics in
colorectal cancer cells and are in accordance with previous
studies suggesting the Raf/Mek/Erk cascade to play a
minor role in chemoresistance [34,35]. Taken together with
the observed differential sensitivity of BRAF-mutant cells
towards starvation-induced apoptosis, these results further
dissect the distinct apoptosis pathways in our model, i.e.
serum-starvation versus chemotherapeutic agents.
Figure 3 Pharmacogenetic characterization of BRAF knockout
cell clones. Cells were incubated with different chemotherapeutic
agents. On day 7 the cells were lyzed and proliferation was determined
by SYBR green I staining of DNA. A-E: No differences in response
were observed between BRAF-mutant and wild-type clones with
mitomycin C, oxaliplatin, paclitaxel, etoposide, or 5-fluorouracil. F: EGFR
expression was verified in all cell clones by Western blotting. No
different proliferation behavior between the corresponding cell
clones was observed upon treatment with monoclonal EGFR antibody
cetuximab in concentrations up to 800 mg/L. As a positive control, the
colorectal cancer cell line Lim1215 was used.
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body therapy has been elucidated recently but remains
poorly understood on the molecular level [2]. Our model
enabled us to specifically analyze BRAF-dependent ef-
fects of cetuximab sensitivity independent of confound-
ing genetic events. RKO cells and derived mutant andwild type clones express the epidermal growth factor re-
ceptor (EGFR) at comparable levels (Figure 3F). To test
whether loss of mutant BRAF might reconstitute respon-
siveness to the inhibition of EGFR, cells were treated
with the monoclonal antibody cetuximab. However, no
difference in proliferation was observed between BRAF
wild-type and mutant cells, while cetuximab sufficiently
inhibited growth of the control cell line Lim1215 [36].
All cells revealed a similar slight decrease in the prolifer-
ation index down to 0.6 at very high concentrations of
cetuximab (Figure 3F). This modest effect might be due
to unspecific toxicity or to dilution, rather than to a spe-
cific anti-proliferative effect of cetuximab, since at 0.8 g/L
the antibody solution accounts for 16% of the culture
medium. These findings are in line with previous studies
showing that resistance against EGFR-targeted treatment
frequently occurs in BRAF-mutant tumors [37].
Next, we investigated the impact of the BRAF V600E-
mutation on several established B-Raf inhibitors. Sorafe-
nib was developed as the first small molecule inhibitor
selectively targeting Raf kinases and has been reported
to inhibit B-Raf [38,39]. However, sorafenib was found
to show a complex inhibition profile affecting various ef-
fector kinases in several cellular signaling pathways and
is therefore considered a multi-kinase inhibitor today
[40]. Recently, it has been shown that PI3K/AKT signal-
ing rather than the Raf/Mek/Erk cascade is both the
main target of sorafenib in apoptosis initiation and a key
player in de novo resistance against sorafenib [41,42]. In
our model, sorafenib suppressed proliferation at antici-
pated concentrations, but elicited no differential effects
between BRAF-mutant and wild-type cells (Figure 4A).
This further supports the mechanism of sorafenib to be
widely independent of Mek 1/2 phosphorylation.
Recently, more selective B-Raf inhibitors have been de-
veloped exhibiting considerable specificity for the V600E
mutant kinase in vitro [43,44]. Testing these compounds
in our model system revealed that vemurafenib and
RAF265 did not have significantly different effects on
proliferation of the RKO-derived clones (Figure 4B and
C). Mechanisms of resistance against B-Raf inhibition
are complex and involve activation of upstream rather
than only downstream effectors of the B-Raf kinase or
can be modulated via other signaling pathways [45,46].
Additionally, resistance against particular B-Raf inhibi-
tors has recently been reported to occur frequently in
colorectal cancer cells [47,48].
In contrast to these compounds, the B-RafV600E inhibi-
tor dabrafenib selectively decreased proliferation of
BRAF-mutant cell clones (Figure 4D). Remarkably, the
IC50 ratio between the wild-type clone RBW-1 and
clones carrying a mutant allele only (RBO-1, RBO-2)
was 20, while it was only 5.3 between RBW-1 and the
heterozygous clones (RKO-E1, RBOW) that carry both
Figure 4 Chemosensitivity for B-Raf inhibitors. A: Multi-kinase inhibitor sorafenib had no differential effect on RKO BRAF knockout cell clones.
B-C: Although no significant differences in the IC50 were observed, by trend RBW-1 was less sensitive to vemurafenib and RAF265 compared to
cells with mutant BRAF alleles. D: The IC50 of the B-Raf kinase inhibitor dabrafenib in RBW-1 was 5.3 times higher than the IC50 of the parental
clones RKO-E1 and RBOW, and 20 times higher than in clones carrying a BRAF-mutant allele only. E: Aliquots of each cell line were incubated with
the respective IC50 concentrations of B-Raf inhibitors, lyzed, and analyzed in Western blots for phosphorylation of Mek 1/2 (upper panel) and Erk
1/2 (lower panel). F: Signal intensities of phospho-Mek 1/2 and phosphor-Erk 1/2 were normalized to the total fractions in densitometric analyses.
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gene-dosage effect [49]. However, since the inhibition
profile of dabrafenib is not yet fully known, a favorable
off-target effect cannot be excluded and should be fur-
ther examined in future studies.
To further investigate the differential effects of the
specific B-RafV600E inhibitors, we examined their specific
impact on downstream effectors of B-Raf. For this pur-
pose, we analyzed the relative phosphorylation levels
of Mek 1/2 and Erk 1/2 in lysates from cells incu-
bated with compound concentrations corresponding to
the previously determined IC50 (Figure 4E upper panel
and Figure 4F left panel). All inhibitors reduced the
relative level of Mek 1/2 phosphorylation in clones carry-
ing the V600E mutation by more than 90% with dabrafe-
nib showing the strongest effect. No reduction of Mek 1/2phosphorylation was observed in RBW-1 BRAFwt/-/- cells.
These data were further confirmed on the level of
phospho-Erk 1/2 (Figure 4E lower panel and Figure 4F
right panel). Taken together, analysis of B-Raf downstream
signaling showed dabrafenib to inhibit the Raf/Mek/Erk
cascade most efficiently. In RBW-1 cells, a paradoxical ele-
vation of phosphorylated Mek 1/2 and Erk 1/2 levels was
observed upon B-Raf inhibition, a phenomenon previously
reported for BRAF wild-type cells [50-52].
PI3K/AKT signaling in corresponding cell clones
Although the MAPK signaling and PI3K/AKT signaling
pathways feature multiple interconnections, they are com-
monly considered as two distinct pathways [53]. Sharing
EGFR as an activating upstream growth factor receptor,
the MAPK and PI3K/AKT axes mediate different cellular
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rather than by exclusive activation of a single cascade [54].
The parental RKO cells harbor prominent mutations in
both axes of this signaling network, namely B-RafV600E and
p110αH1047R. Therefore, the corresponding knockout
clones were tested for differential sensitivity towards inhib-
ition of the PI3K/AKT axis.
A heterozygous mutation of PIK3CA was confirmed in
all RKO-derived cell clones (Figure 5A). Without treat-
ment, phosphorylation of AKT was decreased in BRAF
wild-type cells at both T-308 and at S-473, with the ef-
fects on S-473 being more pronounced (Figure 5B).
Upon treatment with perifosine, an inhibitor of both Erk
1/2 and AKT kinases, no differential sensitivity was ob-
served for BRAF wild-type cells (Figure 5C). Next, the
cells were treated with an inhibitor of the PI3K catalytic
subunit, PI-103, as a more upstream-acting agent. Again,
no differential sensitivity was observed between BRAF-
mutant and wild-type clones (Figure 5D).
In Western blot analyses, no decrease in AKT phos-
phorylation was observed upon treatment with perifo-
sine at IC75 for any of the cell clones (data not shown).
This likely indicates the consistent decrease in proliferation
of the cell clones to be caused by unspecific cell toxicity of
the compound. However, western blot analysis revealed aFigure 5 Analysis of PI3K/AKT signaling. A: Sequencing results for PIK3C
subunit of PI3 kinase are shown as histograms. B: Phospho-protein and tot
differential response between wild-type and BRAF-mutant cell clones was f
phosphorylation of AKT residues T-308 and S-473 in a dose-dependent marobust inhibition of AKT phosphorylation at any applied
concentration of PI-103. Even in wild-type cells, which
showed lower phospho-AKT levels as compared to mutant
cells under standard conditions, phosphorylation of AKT
was further decreased upon PI-103 treatment (Figure 5E).
Combined targeting of MAPK signaling and PI3K/
AKT signaling is considered a promising therapeutic
strategy for tumor cells. Consistently, a combinatorial
approach has recently been shown to synergistically in-
hibit proliferation in RKO cells [55]. While the relatively
high concentration of vemurafenib needed to inhibit cell
proliferation was confirmed in our model, both BRAF
wild-type and BRAF-mutant RKO cells were resistant to
inhibition of PI3K/AKT signaling by PI-103. In con-
trast to pharmaceutical approaches, the genetic BRAF-
knockout inactivates B-RafV600E completely by definition.
Thus, since we show a distinct decrease of AKT phos-
phorylation in RBW-1 cells, the genetic targeting alone
might already represent the effect of a combined inhib-
ition of both signaling pathways. Against this back-
ground, unspecific off-target effects might impact the
unselective pharmaceutical approach, emphasizing the
need for a conscientious molecular characterization of
each compound. However, resistance towards PI-103
treatment in BRAF wild-type cells remains to someA A3140G corresponding to the H1047R mutation in the catalytic
al protein levels for AKT were examined by Western Blotting. C-D: No
ound in proliferation assays. E: In Western blot analysis, PI-103 inhibited
nner in all cell clones.
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genetic defects reported in RKO, including a bi-allelic non-
sense mutation of NF1 [56].
Confirmation of results in independent BRAF-knockout cells
Somatic cell gene targeting is known to provide a high
degree of confidence [57,58] and additionally, genetic
uniformity among our cell clones has been achieved by
subcloning RKO-E1 from the parental cell line. However,
during the course of recombination of the second BRAF
allele, only one BRAF(wt/-/-) clone was gained and verifi-
cation of the results in further clones of each phenotype
was desired [19].
Therefore, we confirmed our data using a panel of
similar RKO BRAF-knockout clones, which were estab-
lished independently in a different lab and published
during the course of our study [20]. Consistent with the
findings from our cells, the BRAF wild-type clone from
the complementary set of cells revealed the highest sub
G1-fraction and strongest PUMA expression levels after
withdrawal of serum as compared to the corresponding
BRAF-mutant clones (Figure 6A). Similarly, no signifi-
cant sensitivity differences were observed for the B-
RafV600E inhibitors RAF265 and vemurafenib between
BRAF-mutant and wild-type clones (Figure 6B and C).
Dabrafenib selectively inhibited growth of cells contain-
ing mutant BRAF alleles at 3-fold lower IC50 as com-
pared to BRAF-mutant clones (Figure 6D). Additionally,
the relative phosphorylation levels of Mek 1/2 and Erk
1/2 were assessed by Western blotting in these cells.
The relative phosphorylation was found to be more effi-
ciently reduced by dabrafenib than by vemurafenib or
RAF256 in BRAF-mutant cells on both Mek 1/2 and Erk
1/2 level, supporting the data obtained with our panel of
corresponding cell clones (Figure 6E-F). However, while
the wild-type clone of the confirmatory cell panel con-
sistently showed the expected MAPK hyperactivation,
the pattern among Mek 1/2 and Erk 1/2 levels differed
markedly compared to our RBW-1 cells. As phosphoryl-
ation levels of these effectors show a complex temporal
pattern, these differences are likely explainable by even
slight variations in sample preparation [54].
Last, the unexpected resistance of RKO-derived BRAF
wild-type cells towards inhibition of PI3K/AKT signaling
was confirmed using the independent BRAF-knockout cell
panel. As observed in our set of cells, no change of IC50
after PI-103 treatment was observed for the wild-type
clone in the confirmatory cell set, while the PIK3CA
phenotype was conserved and AKT phosphorylation was
decreased under basal culture conditions (Figure 6G-I).
Conclusions
Utilizing a BRAF-model of isogeneic cell lines, we provide
evidence that V600E-mutant B-Raf confers independenceof serum-derived growth factors and resistance to
starvation-induced apoptosis, but not chemotherapy-
induced apoptosis, indicating these traits to be main
targets for B-Raf inhibitor therapy. Targeting of mutant
BRAF alleles leads to a loss of these hallmarks of can-
cer. In contrast, B-RafV600E did not affect sensitivity to-
wards conventional chemotherapeutic compounds such
as mitomycin C, oxaliplatin, paclitaxel, etoposide, or
5-fluorouracil in our model. Also, no sensitivity was ob-
served towards the therapeutic EGFR antibody cetuxi-
mab, although the EGF receptor was similarly expressed
in all RKO-derived cell clones. Dissecting the effect of se-
lective B-Raf inhibition, neither vemurafenib nor RAF265
induced proliferation differences among wild-type and
mutant clones. In contrast, dabrafenib exhibited an obvious
BRAF status-dependent inhibitory effect on cell prolifera-
tion. Together with the highly robust molecular effects of
dabrafenib on phospho-Erk and phospho-Mek induction,
this possibly indicates a high specificity of the compound.
On the other hand, off-target effects could also have con-
tributed, since all small molecule kinase inhibitors are
multi-kinase inhibitors to some extent. Kinomic ap-
proaches to obtain detailed inhibition profiles appear as a
promising tool for future studies to reveal the key differen-
tial modes of action between the utilized compounds.
Methods
Tissue culture
Cell culture reagents and antibiotics were purchased
from PAA Laboratories (Pasching, Austria). HEK293 and
RKO were purchased from ATCC (via LGC Standards
GmbH, Wesel, Germany) and validated by DNA profil-
ing at the German Biological Resource Center (DSMZ,
Braunschweig, Germany). Additional RKO clones har-
boring deleted BRAF alleles were kindly provided by B.
Vogelstein (Johns Hopkins University, Baltimore, MD)
HEK293, RKO, and derivative cell clones were maintained
at 37°C in a water-saturated atmosphere containing 5%
CO2 in high glucose (4.5 g/L) DMEM supplemented with
100 units/mL penicillin, 100 mg/L streptomycin, and 10%
FBS if not indicated differently.
Somatic cell gene targeting
For somatic cell gene targeting, the AAV Helper-Free
System (Agilent Technologies, Santa Clara, CA, USA)
was used [18]. The chromosomally stable target cell line
RKO shows slight aneuploidy leading to triplication at the
BRAF locus (dup (7) (q21q36)) [13]. In order to target two
BRAF alleles serially, two AAV targeting constructs were
cloned containing either hygromycin or neomycin resist-
ance. The resistance cassette was flanked by sequences
homologous to regions flanking BRAF exon 15 (Figure 1A).
These homology arms were amplified by PCR using
primer LHA_FW_NotI (atacatac-GCGGCCGC-tgactggagt
Figure 6 Verification of results in independent BRAF knockout cells. A: Cell death was assessed by determining the sub G1-fraction by flow
cytometry and analyzed on a molecular level by Western blotting for PUMA. B-D: In chemosensitivity assays RAF265 and vemurafenib did not induce
different responses, while with dabrafenib, the wild type clone showed a 2.6 fold higher IC50 value as compared to control clones. E-F: In Western
blotting experiments and subsequent densitometry analysis, IC50 concentrations of dabrafenib showed a stronger effect on relative phosphorylation
levels of Mek 1/2 and Erk 1/2 in parental and BRAF-mutant cells than RAF265 and vemurafenib. G: In proliferation assays, no differential responses
were observed for PI-103. H: PIK3CA status was confirmed by sequencing. I: Phosphorylation of AKT was examined by Western blotting.
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TTCCCTTTAG-cattttcctatcagagcaagc), or RHA_FW_
linkB (CGCCCTATAGTGAGTCGTATTAC-gtggatggtaa
gaattgagg) with RHA_RV_NotI (atacatac-GCGGCCGC-
catgagtggcctgtgattc), respectively. Preparation of AAV
particles was done according to Kohli et al [18].
After a limiting dilution of RKO cells, the single clone
RKO-E1 was infected with AAV containing the hyg re-
sistance gene and seeded in a limiting dilution. After
three weeks of incubation with 2.0 g/L hygromycin B,
single colonies were screened with two primer pairs:
LHA-upstream-FW (agggacatggataaataggcttg) combined
with CMV-5′-RV (tagggcgcgataacttcgta) and RHA-
downstream-RV (agcaggccagtcaactcct) in combination
with BGHpA-3′-FW (ccgaggagcaggactgaata). In order
to verify the successful recombination, a genomic region of
approximately 300 bp was amplified with exon 15 flanking
primers BRAF-E15-300-FW (gccccaaaaatcttaaaagca) and
BRAF-E15-300-RV (ctgatgggacccactccat) and was subse-
quently analyzed by DNA sequencing using BRAF-E15-
300-seq (ttattgactctaagaggaaagatgaa).From a clone of the desired BRAF genotype (onco-
genic/wild-type/deleted) the knockout cell line RBOW
(RKO-derived clone BRAFonc/wt/-) was established. RBOW
cells were infected with AAV particles mediating neomy-
cin resistance, diluted and incubated with 4.5 g/L G418
sulphate. For PCR screening of the single colonies,
LHA-upstream-FW was combined with Neo-5′-RV
(gttgtgcccagtcatagccg) and RHA-downstream-RV was
combined with Neo-3′-FW (tcgccttcttgaagagttct). Positive
clones were verified as above. The knockout clones RBO-1,
RBO-2 (RKO-derived clone BRAFonc/-/- 1 and 2) and
RBW-1 (RKO-derived clone BRAFwt/-/- 1) were further
expanded.
Western blotting
Western blot samples were prepared with phospho-
protein lysis buffer. Blocking of the membranes was
done with 5% BSA in TBS-T prior to the detection of
phospho-proteins, or else with 5% skim milk powder in
TBS-T. Antibodies against B-Raf, pan Mek 1/2, phospho-
Mek 1/2, pan Erk 1/2, phospho-Erk 1/2, caspase 3, and
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and 2524) were purchased from Cell Signaling Technolo-
gies (via New England Biolabs GmbH, Frankfurt am Main,
Germany). For detection of EGFR and PUMA item num-
bers sc-03 and sc-374223 from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) were used. Actin was detected with
actin monoclonal antibody from MP Biomedicals (Solon,
OH, USA). Densitometry was done with ImageJ software
by Wayne Rasband.Staining of senescence-associated β-galactosidase activity
Cellular senescence was detected by staining of senescence-
associated β-galactosidase activity at pH 6.0 [25]. To
facilitate detection of positive blue cells, the cells
were counterstained with 0.1% rosinduline in 1% acetic
acid. Cells were air-dried and quantified by bright field
microscopy.Flow cytometry
Flow cytometry was performed either on a BD FACS-
Calibur (BD Biosciences, San Jose, CA, USA) or an Accuri
C6 (BD Bioscience) device. Data analysis was done using
Flowing Software by Perttu Terho and CFlow Plus (BD
Bioscience), respectively.Proliferation and chemosensitivity assays
For proliferation assays, 105 cells were seeded in 6-well
plates in triplicates and incubated for the indicated time
period. Every 24 hours, triplicates were trypsinized and
diluted according to the expected cell yield estimated in
advance by phase-contrast microscopy. For each repli-
cate two aliquots of 10 μL were taken and counted in a
3x3 square hemacytometer. For each triplicate of sample
at each time point, standard error of the mean (SEM)
was calculated.
Chemosensitivity assays were performed using stand-
ard SYBR green cell proliferation assays over a broad
range of concentrations (covering 100% to 0% survival),
as described previously [59,60]. Briefly, cells (1,500–
1,800 per well) were plated in 96-well plates, allowed
to adhere, and subsequently treated. After seven days,
the cells were washed and lyzed in 100 µL of deionized
water, and 0.2% SYBR green I (Lonza Group Ltd., Basel,
Switzerland) was added. Fluorescence was measured
(Cytofluor Series 4000, Applied Biosystems, Darmstadt,
Germany) and growth inhibition calculated as compared
to the untreated control samples. At least three indepen-
dent experiments were performed per agent, with each
data point reflecting triplicate wells. Error bars represent
standard error of the mean (SEM) from three experiments.
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